- Home
- PED vs MOLN Comparison
PED vs MOLN Comparison
Compare PED & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | PED | MOLN |
|---|---|---|
| Founded | N/A | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.8M | 154.2M |
| IPO Year | 2012 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PED | MOLN |
|---|---|---|
| Price | $13.56 | $4.40 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $30.00 | $8.38 |
| AVG Volume (30 Days) | ★ 22.2K | 953.0 |
| Earning Date | 05-15-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $45,751,000.00 | N/A |
| Revenue This Year | $171.75 | N/A |
| Revenue Next Year | N/A | $374.07 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.67 | N/A |
| 52 Week Low | $0.43 | $3.53 |
| 52 Week High | $18.89 | $5.36 |
Technical Indicators
Market Signals| Indicator | PED | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 64.89 | 57.25 |
| Support Level | $12.89 | $4.13 |
| Resistance Level | $13.92 | $4.54 |
| Average True Range (ATR) | 0.72 | 0.03 |
| MACD | 0.35 | 0.02 |
| Stochastic Oscillator | 97.69 | 78.74 |
Price Performance
Historical ComparisonAbout PED Pedevco Corp.
PEDEVCO Corp is an oil and gas company focused on oil and natural gas development, exploration, and production. The company focuses on legacy properties with a long production history, well-defined geology, and existing infrastructure that can be leveraged when applying modern field management technologies. The current properties in the Denver-Julesberg Basin (D-J Basin) in Colorado and Wyoming, the Powder River Basin (PRB) in Wyoming, and the San Andres formation of the Permian Basin situated in West Texas and eastern New Mexico (the Permian Basin).
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.